Lupin Limited (BOM: 500257)

Market Cap	918.55B
Revenue (ttm)	214.31B
Net Income (ttm)	26.26B
Shares Out	456.19M
EPS (ttm)	57.41
PE Ratio	35.08
Forward PE	27.23
Dividend	8.00 (0.40%)
Ex-Dividend Date	Jul 16, 2024

Volume	7,752
Open	2,035.45
Previous Close	2,038.70
Day's Range	2,005.10 - 2,050.75
52-Week Range	1,172.00 - 2,312.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 30, 2024

About Lupin

Lupin Limited, together with its subsidiaries, operates as a pharmaceutical company in India and internationally. It engages in the drug discovery, development, production, marketing, and sale of various branded and generic formulations, biosimilars, over-the-counter and specialty drugs, and active pharmaceutical ingredients (APIs). The company offers formulations for use in the therapeutic areas of anti-tuberculosis, diabetes management, cardiovascular, chronic obstructive pulmonary diseases, asthma, gynecology and women’s health, central nerv...

• Industry: Pharmaceutical Preparations
• Founded: 1968
• Employees: 19,210
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 500257

Financial Performance

In 2023, Lupin's revenue was 200.11 billion, an increase of 20.25% compared to the previous year's 166.42 billion. Earnings were 19.14 billion, an increase of 345.15%.